April industry news: Labcorp announces a first-of-its-kind test for early indication of neurodegenerative diseases and brain injuries

In April’s industry news round-up: Labcorp announces a novel test for early assessment of neurodegenerative diseases and brain injuries; the US FDA grants accelerated approval to new pediatric brain cancer drug; the European Commission grants Orphan Medicinal Product designation for a potential fragile X syndrome treatment; Neurocrine Biosciences reports positive Phase II data for major depressive disorder drug; and the Parkinson’s Foundation and Tasso join forces to accelerate Parkinson’s disease research. Take a look at April’s headlines below: Labcorp announced a first-of-its-kind test for early indication of neurodegenerative diseases and brain injuries US FDA grants accelerated approval to tovorafenib for...